contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lumito-and-atlas-antibodies-enter-strategic-partnership-to-advance-high-resolution-tissue-imaging

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Lumito

Lumito AB (publ) (“Lumito” or the “Company”) and Atlas Antibodies AB (“Atlas Antibodies”) today announce a strategic partnership aimed at accelerating innovation in tissue analysis and strengthening...

<div class="mfn-preamble"><p><strong>Lumito AB (publ) (“Lumito” or the “Company”) and Atlas Antibodies AB (“Atlas Antibodies”) today announce a strategic partnership aimed at accelerating innovation in tissue analysis and strengthening their respective positions in a growing global market. By combining Lumito’s proprietary high-sensitivity imaging technology with Atlas Antibodies’ extensively validated antibody portfolio, the collaboration is designed to create differentiated, value-driven solutions for research, translational applications, and quantitative analysis in tissue samples</strong></p></div><div class="mfn-body"><blockquote>”We are excited to partner with Atlas Antibodies, a company renowned for its scientific rigor and antibody validation standards. By combining our high-resolution imaging technology with Atlas Antibodies’ trusted antibody portfolio, we aim to unlock new possibilities in digital pathology and biomarker research”, says Sanna Wallenborg, CEO of Lumito.</blockquote><blockquote>”Our collaboration with Lumito represents an important step toward enabling next-generation tissue analysis. Together, we can provide researchers with powerful tools that enhance accuracy, reproducibility, and insight in biomarker detection”, says Ingela Hofverberg, CEO of Atlas Antibodies.</blockquote><p><strong>About Atlas Antibodies</strong><br>Atlas Antibodies is a Swedish life science company providing highly validated primary antibodies to researchers worldwide. Built on the Human Protein Atlas project, the company focuses on quality, reproducibility, and comprehensive validation to support reliable scientific discoveries.</p></div><div class="mfn-footer mfn-contacts mfn-1c72a901341e"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Sanna Wallenborg, CEO Lumito<br>E-mail:&nbsp;<a rel="noopener" href="mailto:sw@lumito.se">sw@lumito.se</a><br>Ph: +4670-870 01 68</p></div><div class="mfn-footer mfn-b0f3ca16b45a"><p><strong class="mfn-heading-1">About Lumito</strong><br>Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center.&nbsp;<a rel="noopener" href="http://www.lumito.se/en/">www.lumito.se/en/</a></p><p>The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/fb3ed069-5581-4b67-9b26-65c362425e9d/lumito-and-atlas-antibodies-enter-strategic-partnership-to-advance-high-resolution-tissue-imaging.pdf" class="mfn-generated mfn-primary">Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging</a></p></div>

Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging